Pharmacological consequences of long-term morphine treatment in patients with cancer and chronic non-malignant pain

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Pharmacological consequences of long-term morphine treatment in patients with cancer and chronic non-malignant pain. / Andersen, Gertrud; Sjøgren, Per; Hansen, Steen Honoré; Jensen, Niels-Henrik; Christrup, Lona Louring.

In: European Journal of Pain, Vol. 8, No. 3, 06.2004, p. 263-71.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Andersen, G, Sjøgren, P, Hansen, SH, Jensen, N-H & Christrup, LL 2004, 'Pharmacological consequences of long-term morphine treatment in patients with cancer and chronic non-malignant pain', European Journal of Pain, vol. 8, no. 3, pp. 263-71. https://doi.org/10.1016/j.ejpain.2003.09.003

APA

Andersen, G., Sjøgren, P., Hansen, S. H., Jensen, N-H., & Christrup, L. L. (2004). Pharmacological consequences of long-term morphine treatment in patients with cancer and chronic non-malignant pain. European Journal of Pain, 8(3), 263-71. https://doi.org/10.1016/j.ejpain.2003.09.003

Vancouver

Andersen G, Sjøgren P, Hansen SH, Jensen N-H, Christrup LL. Pharmacological consequences of long-term morphine treatment in patients with cancer and chronic non-malignant pain. European Journal of Pain. 2004 Jun;8(3):263-71. https://doi.org/10.1016/j.ejpain.2003.09.003

Author

Andersen, Gertrud ; Sjøgren, Per ; Hansen, Steen Honoré ; Jensen, Niels-Henrik ; Christrup, Lona Louring. / Pharmacological consequences of long-term morphine treatment in patients with cancer and chronic non-malignant pain. In: European Journal of Pain. 2004 ; Vol. 8, No. 3. pp. 263-71.

Bibtex

@article{f61bcc5f60f14201bcdfef6f9180d35d,
title = "Pharmacological consequences of long-term morphine treatment in patients with cancer and chronic non-malignant pain",
abstract = "In patients with pain of malignant origin morphine may be administered in high and often increasing doses during extended periods of time. In patients with chronic pain of non-malignant origin morphine may be an important remedy, and in these cases the goal is to keep the morphine dose stable. The pharmacokinetic as well as the pharmacodynamic consequences of long-term morphine treatment with special reference to the two most important metabolites of morphine morphine-6-glucuronide (M-6-G) and morphine-3-glucuronide (M-3-G) remain to be settled.",
keywords = "Adult, Aged, Analgesics, Opioid, Chronic Disease, Dose-Response Relationship, Drug, Drug Administration Routes, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Morphine, Morphine Derivatives, Neoplasms, Pain, Pain Measurement, Salivary Glands, Xerostomia",
author = "Gertrud Andersen and Per Sj{\o}gren and Hansen, {Steen Honor{\'e}} and Niels-Henrik Jensen and Christrup, {Lona Louring}",
year = "2004",
month = jun,
doi = "10.1016/j.ejpain.2003.09.003",
language = "English",
volume = "8",
pages = "263--71",
journal = "European Journal of Pain",
issn = "1090-3801",
publisher = "JohnWiley & Sons Ltd",
number = "3",

}

RIS

TY - JOUR

T1 - Pharmacological consequences of long-term morphine treatment in patients with cancer and chronic non-malignant pain

AU - Andersen, Gertrud

AU - Sjøgren, Per

AU - Hansen, Steen Honoré

AU - Jensen, Niels-Henrik

AU - Christrup, Lona Louring

PY - 2004/6

Y1 - 2004/6

N2 - In patients with pain of malignant origin morphine may be administered in high and often increasing doses during extended periods of time. In patients with chronic pain of non-malignant origin morphine may be an important remedy, and in these cases the goal is to keep the morphine dose stable. The pharmacokinetic as well as the pharmacodynamic consequences of long-term morphine treatment with special reference to the two most important metabolites of morphine morphine-6-glucuronide (M-6-G) and morphine-3-glucuronide (M-3-G) remain to be settled.

AB - In patients with pain of malignant origin morphine may be administered in high and often increasing doses during extended periods of time. In patients with chronic pain of non-malignant origin morphine may be an important remedy, and in these cases the goal is to keep the morphine dose stable. The pharmacokinetic as well as the pharmacodynamic consequences of long-term morphine treatment with special reference to the two most important metabolites of morphine morphine-6-glucuronide (M-6-G) and morphine-3-glucuronide (M-3-G) remain to be settled.

KW - Adult

KW - Aged

KW - Analgesics, Opioid

KW - Chronic Disease

KW - Dose-Response Relationship, Drug

KW - Drug Administration Routes

KW - Drug Administration Schedule

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Morphine

KW - Morphine Derivatives

KW - Neoplasms

KW - Pain

KW - Pain Measurement

KW - Salivary Glands

KW - Xerostomia

U2 - 10.1016/j.ejpain.2003.09.003

DO - 10.1016/j.ejpain.2003.09.003

M3 - Journal article

C2 - 15109977

VL - 8

SP - 263

EP - 271

JO - European Journal of Pain

JF - European Journal of Pain

SN - 1090-3801

IS - 3

ER -

ID: 46098448